Just In
- 2 hrs ago Exclusive: On World Malaria Day 2024, Dr Shares Danger Signs Parents Must Watch Out For In Child With Malaria
- 2 hrs ago Exclusive: Expert Debunks 5 Common Misconceptions About Expectant Mothers That You Need To Steer Clear From
- 4 hrs ago Monthly Love Horoscope For May 2024: Virgo Needs To Make Their Partner Feel Secure In Relationships
- 5 hrs ago When Will Vaishakh Month 2024 Start? Vrats And Festivals That Will Fall This Month, Complete List!
Don't Miss
- Technology Infinix GT 20 Pro Launch Confirmed: Full Specifications and Pricing Leaked Ahead of Time
- Finance Gold Prices India: 24K/100 Grams Yellow Metal Falls By Rs 3800, 24K/10 Grams Down By Rs 380
- Sports PAK vs NZ Dream11 4th T20I: Squads, Fantasy Tips & Best Picks for Pakistan vs New Zealand fourth match
- Automobiles 2024 Jeep Wrangler Facelift Video Review: Off-Roading Specialist Gets More Friendly
- Movies Chacha Vidhayak Hain Humare 3 OTT Release Date & Platform: 5 Reasons To Watch Zakir Khan’s Show
- Education UPSC CAPF 2024 registration begins; Apply online for 506 Assistant Commandant posts, Know more
- News 417 Out Of 1192 Candidates In Phase 2 Of Polls Face Criminal Cases, Most From BJP: ADR Data
- Travel Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
Diabetes Medication Could Treat Heart Failure Patients: Study
A medication originally used for patients with Diabetes is the first to help people with heart failure and could revolutionise treatment, according to new research from the University of East Anglia. Early research had shown that Sodium-glucose co-transporter-2 (SGLT2) inhibitors could help around half of heart failure patients - those with a condition known as reduction ejection fraction. But new findings published today show that the medication could be beneficial for all heart failure patients - including those with a second type of heart failure called the preserved ejection fraction.
It is the first drug to provide a real benefit in terms of improving outcomes for these patients. And the research team say it will revolutionise treatment options.
Lead researcher Prof Vass Vassiliou, from UEA's Norwich Medical School and an Honorary Consultant Cardiologist at the Norfolk and Norwich University Hospital, said: "Heart failure is a condition where the heart is not pumping as well as it should, and it affects about one million people in the UK.
"There are two types of heart failure. Heart Failure with a reduction in ejection fraction happens when the heart is unable to pump blood around the body due to a mechanical issue. And heart failure with preserved ejection fraction happens when, despite the heart pumping out blood well, it is not sufficient to provide oxygen to all the parts of the body.
"Patients are equally split between the two types of heart failure.
"For many years there was not a single medicine that could improve the outcome in patients with the second type of heart failure - those patients with preserved ejection fraction.
"This type of heart failure had puzzled doctors, as every medicine tested showed no benefit.
"One class of heart medication, called SGLT2 inhibitors, was initially used for patients with diabetes. However, it was noticed that it also helped patients who had heart failure.
"Previous studies had shown that this medication would be beneficial in heart failure with reduced ejection fraction. But we found that it can also help heart failure patients with preserved ejection fraction."
SGLT2 inhibitors are more commonly known under their trade-names Forxiga (Dapagliflozin), Invokana (Canagliflozin), and Jardiance (Empagliflozin).
The research team undertook a meta-analysis of all studies published in the field and brought together data from almost 10,000 patients. They used statistical modelling to show the specific effect of these medicines.
Prof Vassiliou said: "We found that patients taking SGLT2 inhibitors were 22 per cent less likely to die from heart-related causes or be hospitalised for heart failure exacerbation than those taking placebo.
"This is very important because this is the first medication that can provide a benefit to this previously untreatable group of patients - in terms of heart-related deaths or hospitalisation. This is the first medication that can really improve the outcomes for this patient group and it will revolutionise the treatment offered to heart failure patients," he added.
This study was led by researchers at UEA in collaboration with the Norfolk and Norwich University Hospital, Imperial College London and Imperial College NHS Trust, and Cambridge University Hospitals.
'Sodium Glucose Co-transporter 2 (SGLT2) inhibitors in Heart Failure with Preserved Ejection Fraction: A systematic review and meta-analysis' is published in the European Journal of Preventive Cardiology on December 1, 2021.
- healthExclusive: World Oral Health Day 2024: Doctor Shares How Diabetic Patients Can Maintain Their Oral Health
- healthWhat Is VIP? It Is Not What You Think! This One Is Connected To Blood Glucose, Here's What You Need To Know
- pregnancy parentingWhat Are The 4 Must Have Vitamins For Kids With Diabetes?
- healthDoes This Everyday Cooking Ingredient Trigger Diabetes?
- healthRoller Coaster Effect In Diabetes: Why Does My Blood Sugar Level Go Up And Down, How To Stop It
- healthSinger Shakira Loves These 2 Indian Sweets! How To Make It Diet-Friendly?
- healthWorld Diabetes Day 2023: 3 Weird Things That Can Put You At Risk Of Developing Diabetes
- healthWorld Diabetes Day 2023: Daily Habits That Make One At Risk Of Diabetes
- wellnessWorld Diabetes Day 2023: Avoid These Common Mistakes When Testing Blood Sugar Levels
- healthDiwali 2023: Kalakand Recipe For Diabetic People; It Is Sugar-Free & Keto-Friendly
- healthHow Poor Air Quality During Can Raise Your Diabetes Risk
- healthWhip Up These 3 Diwali Sweets For Your Diabetic Mom Over 40